Volume 26, Issue 4 - Preclinical Studies
Preclinical research in drug development
Abstract
The process of developing a novel drug is time consuming and costly. To increase the chances of successfully completing a clinical trial leading to the approval of a new drug, the choice of appropriate preclinical models is of utmost importance. Identifying a safe, potent, and efficacious drug requires thorough preclinical testing, which evaluates aspects of pharmacodynamics, pharmacokinetics, and toxicology in in vitro and in vivo settings. Nevertheless, merely a small fraction of investigational new drugs tested in clinical trials after passing preclinical evaluation eventually lead to a marketed product. Hence, there is a need for optimising current standard preclinical approaches to better mimic the complexity of human disease mechanisms.
Download the full article
References
-
Ng R. Drugs: From discovery to approval. 3rd ed. New Jersey: Wiley-Blackwell; 2015.
Available from: http://
-
Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011;162(6):1239–49.
Available from: http://
-
European Medicines Agency. ICH Topic E 8 General Considerations for Clinical Trials. 1998 [cited 2017 September 10]. Available from: http://www.emea.eu.int. Published 1998.
Available from: http://
-
Friedman LM, Furberg CD, Demets DL. Fundamentals of clinical trials. 4th ed. New York: Springer Science+Business Media LLC; 2010.
Available from: http://
-
U.S. Food & Drug Administration. The Drug Development Process – Step 2: Preclinical Research. 2017. [cited 2017 September 10].
Available from: https://www.fda.gov/forpatients/ approvals/drugs/ucm405658.htm
-
U.S. Food & Drug Administration. The Drug Development Process - Step 3: Clinical Research. 2017. [cited 2017 September 10].
Available from: https://www.fda.gov/ForPatients/ Approvals/Drugs/ucm405622.htm
-
Waller DG, Sampson T. Medical pharmacology and therapeutics E-Book. Elsevier Health Sciences; 2017.
Available from: http://
-
Fitzpatrick S. The clinical trial protocol. Buckinghamshire: Institute of Clinical Research; 2005.
Available from: http://
-
Faqi AS, ed. A comprehensive guide to toxicology in preclinical drug development. Waltham, MA: Elsevier; 2013.
Available from: http://
-
Everitt JI. The future of preclinical animal models in pharmaceutical discovery and development: A need to bring in cerebro to the in vivo discussions. Toxicol Pathol. 2015;43(1):70–7.
Available from: http://
-
Herter-Sprie GS, Kung AL, Wong KK. New cast for a new era: Preclinical cancer drug development revisited. J Clin Invest. 2013;123(9):3636–45.
Available from: http://
-
Vandamme T. Use of rodents as models of human diseases. J Pharm Bioallied Sci. 2014;6(1):2.
Available from: http://
-
Hoffman RM. Patient-derived orthotopic xenografts: Better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer. 2015;15(8):451–2.
Available from: http://
-
Amberg A. In silico methods. In: Vogel HG, Maas J, Hock FJ, Mayer D, eds. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Berlin, Heidelberg: Springer; 2013:1273–96.
Available from: http://
-
Day CP, Merlino G, Van Dyke T. Preclinical mouse cancer models: A maze of opportunities and challenges. Cell. 2015;163(1):39–53.
Available from: http://
-
Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30(7):679–92.
Available from: http://